Federal funding will support vaccine development as well as manufacturing and delivery of 100 million doses.
Sanofi and GlaxoSmithKline have struck a $2.1 billion deal with the U. S. government to develop and manufacture a vaccine for the coronavirus. The deal, the largest yet from the federal government for a vaccine, is part of Operation Warp Speed, the effort to develop multiple COVID-19 vaccines simultaneously.
The European drugmakers said Friday in a statement that more than half the funding will support further development of the vaccine. The remainder will be earmarked for manufacturing and delivery of an initial 100 million doses.
The deal comes days after Pfizer signed a $1.
